Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation

被引:22
|
作者
Balci, Kevser Gulcihan [1 ]
Balci, Mustafa Mucahit [1 ]
Canpolat, Ugur [1 ]
Sen, Fatih [1 ]
Akboga, Mehmet K. [1 ]
Suleymanoglu, Muhammed [1 ]
Kuyumcu, Serdar [1 ]
Maden, Orhan [1 ]
Selcuk, Hatice [1 ]
Selcuk, Mehmet Timur [1 ]
机构
[1] Turkiye Yuksek Ihtisas Res & Educ Hosp, Dept Cardiol, Ankara, Turkey
关键词
atrial fibrillation; warfarin; apixaban; dabigatran; quality of life; anxiety; HOSPITAL ANXIETY; DEPRESSION; GUIDELINES; MANAGEMENT; VALIDITY; THERAPY; DISEASE; IMPACT;
D O I
10.5152/AnatolJCardiol.2015.6334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare health-related quality of life (HRQoL) measures between novel oral anticoagulants (NOACs) and warfarin-treated Turkish patients who had been started on oral anticoagulants (OACs) due to non-valvular atrial fibrillation (AF) and to determine the effects of OACs on patient's emotional status, anxiety and depression. Methods: A total of 182 patients older than 18 years with non-valvular AF and being treated with OACs for at least 6 months according to current AF guidelines who were admitted to outpatient clinics between July 2014 and January 2015 were included in this cross-sectional study. The exclusion criteria were receiving OACs for conditions other than non-valvular AF and being unable to answer the questionnaire. A questionnaire was administered to all participants to evaluate HRQoL, depression and anxiety. The mean differences between the groups were compared using Student's t-test; the Mann-Whitney U test was applied for comparisons of the medians. Results: The annual number of hospital admissions was significantly higher in the warfarin group (p<0.001), and all HRQoL scores were significantly lower and Hospital Anxiety and Depression Scale (HADS) score was higher in the warfarin group (p<0.001). History of any type of bleeding was significantly higher in the warfarin group (p<0.001). However, none of the patients had major bleeding. Among patients who experienced bleeding, all HRQoL scores were significantly lower and HADS score was significantly higher (p<0.001 and p=0.002, respectively). Conclusion: Warfarin-treated patients had higher levels of self-reported symptoms of depression and anxiety and compromised HRQoL when compared with NOAC-treated patients. The results may be explained by higher rates of bleeding episodes and higher number of hospital admissions, which may cause restrictions in life while on warfarin treatment.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [1] Novel oral anticoagulants in non-valvular atrial fibrillation
    Potpara, Tatjana S.
    Lip, Gregory Y. H.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 115 - 129
  • [2] Novel Anticoagulants for Non-valvular Atrial Fibrillation
    Xu, Bo
    Whitbourn, Robert
    HEART LUNG AND CIRCULATION, 2012, 21 (08) : 463 - 467
  • [3] Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation
    Singh, Sheldon M.
    Wijeysundera, Harindra C.
    CURRENT CARDIOLOGY REPORTS, 2015, 17 (08)
  • [4] Comparison of healthcare costs among patients with non-valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant
    Franchino-Elder, Jessica
    Gilligan, Adrienne
    Song, Xue
    Hartaigh, Briain O.
    Henriques, Caroline
    Sainski-Nguyen, Amy
    Wang, Cheng
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2020, 11 (02) : 133 - 140
  • [5] Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
    Birkinshaw, Alexander
    Fry, Christopher H.
    Fluck, David
    Sharma, Pankaj
    Han, Thang S.
    JRSM CARDIOVASCULAR DISEASE, 2020, 9
  • [6] Permanent discontinuation of non vitamin K oral anticoagulants in real life patients with non-valvular atrial fibrillation
    Vedovati, Maria Cristina
    Verdecchia, Paolo
    Giustozzi, Michela
    Molini, Gabriella
    Conti, Serenella
    Pierpaoli, Lucia
    Valecchi, Francesca
    Aita, Adolfo
    Agnelli, Giancarlo
    Becattini, Cecilia
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 236 : 363 - 369
  • [7] Health-related quality of life among atrial fibrillation patients using warfarin therapy
    Radaideh, Khaldoon M.
    Matalqah, Laila M.
    EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2018, 15 (01): : e12763 - 1
  • [8] New anticoagulants in patients with non-valvular atrial fibrillation
    Zellerhoff, S.
    Lewalter, T.
    Eckardt, L.
    Treszl, A.
    Wegscheider, K.
    Breithardt, G.
    NERVENHEILKUNDE, 2012, 31 (11) : 813 - 820
  • [9] Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
    Masotti, Luca
    Di Napoli, Mario
    Ageno, Walter
    Imberti, Davide
    Becattini, Cecilia
    Paciaroni, Maurizio
    Godoy, Daniel Augustin
    Cappelli, Roberto
    Landini, Giancarlo
    Panigada, Grazia
    Iori, Ido
    Prisco, Domenico
    Agnelli, Giancarlo
    ITALIAN JOURNAL OF MEDICINE, 2013, 7 : 8 - 21
  • [10] New oral anticoagulants in non-valvular atrial fibrillation
    Francia P.
    Adduci C.
    Santini D.
    Musumeci B.
    Tocci G.
    High Blood Pressure & Cardiovascular Prevention, 2013, 20 (2) : 53 - 60